JMP Securities Maintains Market Outperform on HOOKIPA Pharma, Lowers Price Target to $23
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst Jason Butler maintains a Market Outperform rating on HOOKIPA Pharma (NASDAQ:HOOK) but lowers the price target from $50 to $23.
July 26, 2024 | 6:14 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JMP Securities maintains a Market Outperform rating on HOOKIPA Pharma but lowers the price target from $50 to $23.
The Market Outperform rating suggests positive sentiment, but the significant reduction in the price target from $50 to $23 indicates a reassessment of the company's valuation. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100